Hormones and Agents Affecting Hormonal Mechanism: Calcium Regulating Agents
OEVIS1 “Evista FC tablet” 60 mg/tab
適應症：預防及治療停經後婦女骨質疏鬆症。
Usual dose:
Postmenopausal osteoporosis: 60 mg qd; supplemental calcium and/or vitamin D may be required.
Contraindication:
Venous thromboembolic events (active or past history), including deep vein thrombosis, pulmonary embolism, and retinal vein thrombosis; increased risk, especially in first four months of therapy.
Adverse effect:
Common: hot sweats, leg cramp.
Serious: deep venous thrombosis, venous thromboembolism, cerebrovascular accident, thrombosis of retinal vein, pulmonary embolism.
健保使用規範：
1.限用於停經後婦女（alendronate及zoledronate亦可使用於男性）因骨質疏鬆症（須經DXA 檢測BMD之T score≦ -2.5SD）引起脊椎或髖部骨折，或因骨質疏少症(osteopenia)(經DXA檢測BMD之-2.5SD <T score <-1.0SD)引起脊椎或髖部2處或2次(含)以上之骨折。（101/5/1）
2.治療時，一次限用一項藥物，不得併用其他骨質疏鬆症治療藥物。
Related Entries
(Visited 65 times, 1 visits today)